Home › Emphysema › Alabama › Birmingham
Emphysema clinical trials in Birmingham, AL
4 studies for Emphysema are looking for participants at sites in and around Birmingham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
RecruitingPhase 2
- University of Alabama at Birmingham, Birmingham
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
RecruitingPhase 3
- GC2501 Study Site 106, Birmingham
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
Recruiting
- University of Alabama at Birmingham, Birmingham
PiMZ Longitudinal Cohort (PiMZ Logic)
RecruitingObservational study
- University of Alabama at Birmingham, Birmingham
About Emphysema
Emphysema is a type of COPD. COPD makes it hard to breathe. The most common cause of Emphysema is smoking. Learn about symptoms and treatment.
More about Emphysema on MedlinePlus
Emphysema trials in other cities
- Boston, MA8 studies
- Chicago, IL7 studies
- Philadelphia, PA4 studies
- Houston, TX4 studies
- Pittsburgh, PA4 studies
- Orlando, FL4 studies
- New York City, NY3 studies
- Phoenix, AZ3 studies
- Dallas, TX3 studies
- Cleveland, OH3 studies
- Milwaukee, WI3 studies
Other studies in Birmingham
- Cancer (all types)30 studies
- Breast Cancer24 studies
- Obesity23 studies
- Ovarian Cancer23 studies
- Non-Small Cell Lung Cancer22 studies
- Acute Myeloid Leukemia21 studies
- Multiple Myeloma18 studies
- COPD17 studies
- Cardiovascular Disease17 studies
- Overweight16 studies
- Endometrial Cancer16 studies
- Type 2 Diabetes16 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.